|Day Low/High||71.82 / 74.15|
|52 Wk Low/High||69.72 / 89.70|
Among other things, the president works to align Democratic senators to support his massive Covid relief bill.
This is my fifth worst performing position in a book that contains 62 open positions.
Experts pick their favorite long-term investments in medical diagnostics, testing and laboratory services.
Market leadership may be lacking on Thursday despite rising trading volumes, plus an update on Apple, Microsoft, Mastercard, Amazon and Gilead.
After a strong day for fixed-income markets, let's learn from 2008 how to play this volatility.
What if a stock is being propelled by actual events or changes?
BAX saw shares plunge 10% last week on news of accounting irregularities and the charts appear bearish.
BAX is now in a weak technical position.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Straying from these names could land you in quicksand as the 4th quarter begins.
For most of this year the market has been led by growth stocks.
BAX declined recently to break the rising 50-day moving average line.
When chartists look for the next market leaders they often go to stocks that have held up the best during corrections.
When rates decline, most of the S&P 500 benefits, according to TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer.
The crash of oil will only accelerate the move.
I still also use Graham-inspired stock screens, including one based on his 'stocks for the defensive investor' methodology.
It is incredibly healthy to see so many stocks so strong, from so many sectors.
It's a wonder to me how split this market really is.
These four stocks are showing short-term gain catalysts and longer-term growth potential.
Their overseas business has been carrying them.
We know that we are in the era when index managers are ascendant.
Five names to consider from my 'stocks for the defensive investor' screen.
Recent upside breakout refreshes bull trend.
There are nearly too many surging sectors to count.
Baxter buys generic drug maker Claris Injectables in a deal that will be accretive to earnings.